Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1443-1450

  Molassiotis, Alex ^a   Nguyen, Allison Martin ^b   Rittenberg, Cynthia N ^c   Makalinao, Alex ^d   Carides, Alexandra ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Rittenberg Oncology Consulting   (United States)

^d California Hematology   (United States)

^e TEMPLE UNIVERSITY   (United States)

Author keywords

antiemetic; nausea; patient outcomes; quality of life; vomiting

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; ONDANSETRON; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; FUNCTIONAL LIVING INDEX EMESIS SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MORPHOLINES; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 84885625056     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.155     Document Type: Article

References (35)

1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer 15, 497-503 (2007) (Pubitemid 46570778)
2. Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100, 2261-2268 (2004) (Pubitemid 38580348)
3. Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support. Care Cancer 13, 277-286 (2005) (Pubitemid 40674832)
4. Molassiotis A, Saunders MP, Valle J et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support. Care Cancer 16, 201-208 (2008)
5. Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual. Life Outcomes 1, 46 (2003)
6. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. 24, 4472-4478 (2006) (Pubitemid 46630986)
7. Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support. Care Cancer 4, 435-439 (1996) (Pubitemid 126470385)
8. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res. 1, 331-340 (1992)
9. Morrow GR, Roscoe JA, Hickok JT et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology 12(Suppl. 4), 32-37 (1998)
10. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support. Care Cancer 5, 307-313 (1997)
11. Early study of 832 chemotherapy-naive cancer patients correlating chemotherapyinduced nausea and vomiting (CINV) symptoms following moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) with deterioration of physical and cognitive function and global quality of life
12. Osoba D, Hsu MA, Copley-Merriman C et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual. Life Res. 15, 273-283 (2006) (Pubitemid 43226934)
13. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010)
14. Clinical practice guidelines from the Multinational Association for Supportive Care in Cancer and the European Society of Medical Oncology for the prevention of CINV
15. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29, 4189-4198 (2011)
16. Update on American Society of Clinical Oncology clinical practice guidelines for the use of antiemetics in cancer based on a systematic review of 37 clinical trials
17. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69, 1853-1878 (2009)
18. Comprehensive review of aprepitant and its use in the prevention of nausea and vomiting
19. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21, 4112-4119 (2003) (Pubitemid 46606178)
20. Primary article regarding the safety and efficacy of an aprepitant regimen (aprepitant, ondansetron and dexamethasone) versus standard therapy (ondansetron and dexamethasone) in the prevention of CINV in patients receiving high-dose cisplatin.One of the HEC trials from the Phase III aprepitant clinical trial program was included in this report and was conducted in the USA and in 14 other countries
21. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97, 3090-3098 (2003) (Pubitemid 36676265)
22. Primary article regarding the safety and efficacy of an aprepitant regimen (aprepitant, ondansetron and dexamethasone) versus standard therapy (ondansetron and dexamethasone) in the prevention of CINV in patients receiving high-dose cisplatin. One of the HEC trials from the Phase III aprepitant clinical trial program was included in this report and was conducted in eight countries in Latin America
23. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support. Care Cancer 18, 423-431 (2010)
24. Primary article regarding the safety and efficacy of an aprepitant regimen (aprepitant, ondansetron and dexamethasone) versus standard therapy (ondansetron and dexamethasone) in the prevention of CINV in patients receiving MEC. The MEC trial from the Phase III aprepitant clinical trial program was included in this report
25. Yeo W, Mo FK, Suen JJ et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res. Treat. 113, 529-535 (2009)
26. Longo F, Mansueto G, Lapadula V et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support. Care Cancer 19, 1159-1164 (2011)
27. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J. Natl Cancer Inst. 104, 1280-1292 (2012)
28. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15, 103-109 (1997) (Pubitemid 27020563)
29. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur. J. Cancer 41, 1278-1285 (2005) (Pubitemid 40813003)
30. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support. Care Cancer 11, 522-527 (2003) (Pubitemid 36994435)
31. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279-284 (2001) (Pubitemid 33000466)
32. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23, 2822-2830 (2005) (Pubitemid 46179473)
33. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol. 17, 1000-1006 (2006) (Pubitemid 43778994)
34. Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA. Understanding the concept of chemotherapy-related nausea: the patient experience. Eur. J. Cancer Care 17, 444-453 (2008)
35. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49, 295-304 (1992).